Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Amarin Corporation plc (AMRN)

1.54   -0.09 (-5.52%) 03-17 16:00
Open: 1.63 Pre. Close: 1.63
High: 1.63 Low: 1.54
Volume: 1,668,783 Market Cap: 625(M)

Technical analysis

as of: 2023-03-20 8:44:02 AM
Overall:       
Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 2.21     One year: 2.53
Support: Support1: 1.46    Support2: 1.21
Resistance: Resistance1: 1.89    Resistance2: 2.17
Pivot: 1.76
Moving Average: MA(5): 1.56     MA(20): 1.77
MA(100): 1.51     MA(250): 1.65
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 14.5     %D(3): 11.9
RSI: RSI(14): 37.9
52-week: High: 3.74  Low: 1.03
Average Vol(K): 3-Month: 4,813 (K)  10-Days: 4,556 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ AMRN ] has closed above bottom band by 19.0%. Bollinger Bands are 88.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.63 - 1.64 1.64 - 1.65
Low: 1.52 - 1.53 1.53 - 1.54
Close: 1.53 - 1.54 1.54 - 1.55

Company Description

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Headline News

Sun, 19 Mar 2023
Validea's Top Ten Healthcare Stocks Based On Peter Lynch - 3/19 ... - Nasdaq

Thu, 16 Mar 2023
Reconstituted Amarin Board Ready for the Challenge of Unlocking True Potential of VASCEPA®/VAZKEPA® (Icosapent Ethyl) - Yahoo Finance

Mon, 13 Mar 2023
Amarin Co. plc (NASDAQ:AMRN) Sees Large Growth in Short Interest - MarketBeat

Mon, 06 Mar 2023
Amarin touts in vitro data on omega-3 fatty acid EPA in reducing ... - Seeking Alpha

Thu, 02 Mar 2023
Amarin's (AMRN) Q4 Earnings and Revenues Beat Estimates - Nasdaq

Wed, 01 Mar 2023
2023-03-01 | NDAQ:AMRN | Press Release | Amarin Corporation plc - Stockhouse

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 406 (M)
Shares Float 375 (M)
% Held by Insiders 0.4 (%)
% Held by Institutions 34.2 (%)
Shares Short 14,520 (K)
Shares Short P.Month 12,620 (K)

Stock Financials

EPS -0.25
EPS Est Next Qtl -0.03
EPS Est This Year -0.21
EPS Est Next Year -0.06
Book Value (p.s.) 1.47
Profit Margin (%) -28.7
Operating Margin (%) -20.2
Return on Assets (ttm) -4.8
Return on Equity (ttm) -16.8
Qtrly Rev. Growth -37.5
Gross Profit (p.s.) 0.64
Sales Per Share 0.9
EBITDA (p.s.) -0.18
Qtrly Earnings Growth -94.2
Operating Cash Flow -180 (M)
Levered Free Cash Flow -86 (M)

Stock Valuations

PE Ratio -6.16
PEG Ratio -0.4
Price to Book value 1.04
Price to Sales 1.69
Price to Cash Flow -3.48

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.